Phase II trials: the PETREMAC trial, included 222 patients with stage II/III breast cancer, that were stratified to eight different neoadjuvant treatment regimens based on estrogen and progesterone receptors, HER2 expression as well as TP53 mutational status. This evidence concerns the gene ERBB2 and breast carcinoma.